Bay­er to dump $2.26B in­to man­u­fac­tur­ing re­align­ment as it says good­bye to some sites

Bay­er is ready to pour bil­lions more in­to its phar­ma man­u­fac­tur­ing op­er­a­tions, but with that, it will cut ties with sev­er­al sites it al­ready owns.

Bay­er will in­vest more than $2.26 bil­lion in its phar­ma­ceu­ti­cal man­u­fac­tur­ing over the next three years, as it ex­pands in both Eu­rope and the US. Ex­pan­sions in Bergka­men, Berlin, Lev­erkusen, Weimar and Wup­per­tal were al­ready an­nounced ear­li­er in March in a Ger­man-on­ly state­ment, stat­ing that it will mod­ern­ize fa­cil­i­ties and work on “more in­ten­sive col­lab­o­ra­tion” with area uni­ver­si­ties and star­tups.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA